S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME

Benzer Materyaller

• HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial
  Yazar:: Nathalie Dhedin, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-12-01)
• Hematopoietic Cell Transplantation for Sickle Cell Disease
  Yazar:: Gregory Michael Taylor Guilcher
  Baskı/Yayın Bilgisi: (2026-05-01)
• The Immunobiology of HLA-Haploidentical Hematopoietic Cell Transplantation
  Baskı/Yayın Bilgisi: (2020)
• Alternative donor: αβ/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease
  Yazar:: Juergen Foell, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-04-01)
• ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): A FEASIBLE CURATIVE OPTION WITH HLA-IDENTICAL OR HAPLOIDENTICAL DONORS
  Yazar:: RV Gouveia, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-10-01)